Key Insights

Highlights

Treatment Research

1 treatments under study, led by Fe 203799

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Withdrawn1

Clinical Trials (1)

Showing 1 of 1 trials
NCT03417765Phase 1/2Withdrawn

Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas

Showing all 1 trials

Research Network

Common Treatments

  • Fe 2037991

Active Sponsors

  • GlyPharma Therapeutics1
  • VectivBio AG1

Top Investigators

Related Conditions

  • Lymphoma Nonhodgkins Adult1

Activity Timeline